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Vitamin K supplementation and vascular health after kidney 
transplantation: Authors’ response
To the Editor:
We thank Drs te Velde- Keyzer and de Borst1 for their inter-
est in our trial. We agree that in the small, heterogeneous cohort 
of kidney transplant recipients (KTR) in ViKTORIES, the lack of 
evidence of benefit of vitamin K supplementation does not rule 
out a possible role for vitamin K to improve vascular health in spe-
cific circumstances or populations. However, we note that Drs te 
Velde- Keyzer and de Borst do not provide evidence of any clinical 
trials, where this effect has been demonstrated in patients with 
kidney failure. Instead, they quote observational data, and a trial 
which demonstrated that vitamin K2 supplementation decreased 
desphospho- undercarboxylated Matrix Gla Protein (dp- ucMGP) in 
patients on dialysis, but did not assess any measure of vascular 
calcification.2
Vascular calcification is more commonly detected in KTR with 
cardiometabolic comorbidity.3 ViKTORIES participants had evidence 
of excess vascular stiffness (higher than the expected normal range 
and 95% confidence limits for age and sex) and calcification (>75% 
of that expected for age and sex) in 27.8% and 67.8%, respectively. 
There was a statistical multiplicative interaction between baseline 
dp- ucMGP, duration of end- stage kidney disease and vascular calci-
fication (p = .017), but not vascular stiffness (p = .480). There may 
be a heavier baseline burden of vascular stiffness and calcification 
in ViKTORIES participants than in other populations of KTR. In a 
recent meta- analysis, 32% of KTR had detectable vascular calcifi-
cation in the abdominal aorta, though calcification severity was not 
consistently reported across studies.3
Vitamin K deficiency, as assessed by dp- ucMGP, was only de-
tectable in our study in 32.2% of participants, though a greater pro-
portion may have had biochemical evidence of vitamin K deficiency 
if we had been able to measure dp- ucMGP below 900 pmol/L. The 
threshold of dp- ucMGP > 500 pmol/L for vitamin K deficiency, sug-
gested by Drs te Velde- Keyzer and de Borst,1 is supported by a study 
in adults with diabetes, with and without kidney disease.4
Detecting vitamin K deficiency in clinical trials and clinical 
practice requires an available, reliable, and consistently reproduc-
ible test. dp- ucMGP is considered to be the most sensitive marker 
to detect subclinical vitamin K deficiency, the IDS®- iSYS InaKtif 
assay is the only commercially available system to measure this 
biomarker and the lowest calibration threshold for the assay is set 
at 920 pmol/L.4 We believe that this assay needs to be more ro-
bustly calibrated to values below 900 pmol/L, particularly as the 
threshold for vitamin K deficiency is considered to be substantially 
lower.
Importantly, in two separate, recent trials of vitamin K supple-
mentation in patients requiring dialysis (therefore similar to partic-
ipants in ViKTORIES), vitamin K supplementation with vitamin K2 
had no effect on coronary arterial and abdominal aortic calcification 
compared to placebo.5,6
Vitamin K supplementation provided earlier in the disease course 
before vascular stiffness and calcification become established, and/
or in populations with clear evidence of vitamin K deficiency, may 
yet be associated with a clinical benefit. We, and others, have not 
been able to establish this in clinical trials in patients with kidney 
failure requiring dialysis, or in KTR.
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